Breast Cancer Research and Treatment

, Volume 116, Issue 1, pp 113–123 | Cite as

Cognitive impairments associated with breast cancer treatments: results from a longitudinal study

Clinical Trial

Abstract

Purpose Published cross-sectional studies have revealed that chemotherapy for breast cancer is associated with significant cognitive impairments. However, because these studies included no baseline assessment, it is unknown whether the cognitive impairments were pre-existent to cancer treatment or truly secondary to chemotherapy. To resolve this issue, this prospective study aimed to compare the effects of chemotherapy to the effect of radiotherapy on cognitive functioning in women treated for non-metastatic breast cancer. Patients and Methods A total of 81 breast cancer patients, 41 receiving chemotherapy as part of their breast cancer treatment regimen and 40 receiving radiotherapy without chemotherapy were evaluated using an extensive battery of neuropsychological tests at baseline (ie, pre-chemotherapy or pre-radiotherapy), post-treatment (ie, post-chemotherapy or post-radiotherapy) and at a 3-month follow-up assessment. Results A mixed model covariance analysis revealed that receiving any kind of breast cancer treatment, with chemotherapy or not, was associated with impaired capacities for recruiting information in verbal memory. Moreover, the results showed that verbal fluency was impaired after breast cancer treatment, but only in patients who received chemotherapy. Conclusion Overall, this study reveals subtle cognitive impairments associated with breast cancer treatment. Specifically, it suggests that chemotherapy has a specific negative effect on verbal fluency, that breast cancer treatment in general negatively affects verbal memory, but that other cognitive functions are well preserved. Future studies should, however, attempt to better control the practice effect that may have masked other subtle alterations and use more ecologically valid measures of cognitive functioning.

Keywords

Breast cancer Cancer treatments Chemotherapy Radiotherapy Cognitive functioning Cognitive impairments Longitudinal study 

References

  1. 1.
    Berglund G, Bolund C, Fornander T et al (1991) Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27:1075–1081PubMedCrossRefGoogle Scholar
  2. 2.
    Ahles TA, Saykin AJ, Furtenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493. doi:10.1200/JCO.20.2.485 PubMedCrossRefGoogle Scholar
  3. 3.
    Brezden CB, Phillips KA, Abdolell M et al (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMedGoogle Scholar
  4. 4.
    Schagen SB, van Dam FS, Muller MJ et al (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Am Cancer Soc 85:640–650Google Scholar
  5. 5.
    Tchen N, Juffs HG, Downie FP et al (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183. doi:10.1200/JCO.2003.01.119 PubMedCrossRefGoogle Scholar
  6. 6.
    van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218. doi:10.1093/jnci/90.3.210 PubMedCrossRefGoogle Scholar
  7. 7.
    Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61–66. doi:10.1002/pon.2960040108 CrossRefGoogle Scholar
  8. 8.
    Bender CM, Sereika SM, Berga SL et al (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15:422–430. doi:10.1002/pon.964 PubMedCrossRefGoogle Scholar
  9. 9.
    Hermelink K, Untch M, Lux MP et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913. doi:10.1002/cncr.22610 PubMedCrossRefGoogle Scholar
  10. 10.
    Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834. doi:10.1038/sj.bjc.6603029 PubMedCrossRefGoogle Scholar
  11. 11.
    Schagen SB, Muller MJ, Boogerd W et al (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98:1742–1745PubMedCrossRefGoogle Scholar
  12. 12.
    Shilling V, Jenkins V, Morris R et al (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast 14:142–150. doi:10.1016/j.breast.2004.10.004 PubMedCrossRefGoogle Scholar
  13. 13.
    Stewart A, Collins B, Mackenzie J et al (2007) The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 17:1–9Google Scholar
  14. 14.
    Wefel JS, Lenzi R, Theriault RL et al (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299. doi:10.1002/cncr.20272 PubMedCrossRefGoogle Scholar
  15. 15.
    Osterrieth PA (1944) Le test de copie d’une figure complexe: contribution à l’étude de la perception et de la mémoire. Arch Psychol 30:205–353Google Scholar
  16. 16.
    Rey A (1941) L’examen psychologique dans les cas d’encéphalopathie traumatique. Arch Psychol 28:286–340Google Scholar
  17. 17.
    Taylor LB (1979) Localization of cerebral lesions by psychological testing. Clin Neurosurg 16:269–287Google Scholar
  18. 18.
    Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, ParisGoogle Scholar
  19. 19.
    Reitan RM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8:271–276CrossRefGoogle Scholar
  20. 20.
    Smith A (1982) Symbol Digit Modalities Test (SDMT). Manual (revised). Western Psychological Services, Los AngelesGoogle Scholar
  21. 21.
    Wechsler D (1987) Wechsler memory scale-revised. The Psychological Corporation, San AntonioGoogle Scholar
  22. 22.
    des Rosiers G, Kavanagh D (1987) Cognitive assessment in closed head injury: stability, validity and parallel forms for two neuropsychological measures of recovery. Int J Clin Neuropsychol 9:162–173. doi:10.1080/01688638708405356 CrossRefGoogle Scholar
  23. 23.
    Ruff RM, Niemann H, Allen CC et al (1992) The Ruff 2 and 7 selective attention test: a neuropsychological application. Percept Mot Skills 75:1311–1319. doi:10.2466/PMS.75.8.1311-1319 PubMedCrossRefGoogle Scholar
  24. 24.
    Broadbent D, Cooper PF, FitzGerald P et al (1982) The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21:1–16PubMedGoogle Scholar
  25. 25.
    Aaronson NK, Ahmedzai S, Bergman B (1993) The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. doi:10.1093/jnci/85.5.365 PubMedCrossRefGoogle Scholar
  26. 26.
    Wechsler D (1997) Wechsler adult intelligence scale-III. The Psychological Corporation, San AntonioGoogle Scholar
  27. 27.
    Tabachnick BG, Fidell LS (2001) Using multivariate statistics, 4th edn. Allyn & Bacon, New YorkGoogle Scholar
  28. 28.
    SAS Institute (2005) SAS/STAT 9.1 user’s guide: volumes 1 to 7. SAS Institute, Cary, NCGoogle Scholar
  29. 29.
    Little RJA, Schenker N (1995) Missing data. In: Arminger G, Clogg CC, Sobel ME (eds) Handbook of statistical modeling for the social and behavioral sciences. Plenum Press, New York, pp 39–75Google Scholar
  30. 30.
    Frigon J-Y, Laurencelle L (1993) Analysis of covariance: a proposed algorithm. Educ Psychol Meas 53:1–18. doi:10.1177/0013164493053001001 CrossRefGoogle Scholar
  31. 31.
    Bird KD (2002) Confidence intervals for effect sizes in analysis of variance. Educ Psychol Meas 62:197–226. doi:10.1177/0013164402062002001 CrossRefGoogle Scholar
  32. 32.
    Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hilesdale NJGoogle Scholar
  33. 33.
    Basso MR, Bornstein RA, Lang JM (1999) Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 13:283–292. doi:10.1076/clin.13.3.283.1743 PubMedGoogle Scholar
  34. 34.
    McCaffrey RJ, Westervelt HJ (1995) Issues associated with repeated neuropsychological assessments. Neuropsychol Rev 5:203–220. doi:10.1007/BF02214762 PubMedCrossRefGoogle Scholar
  35. 35.
    Falleti MG, Sanfilippo A, Maruff P et al (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59:60–70. doi:10.1016/j.bandc.2005.05.001 PubMedCrossRefGoogle Scholar
  36. 36.
    Cimprich B, Ronis DL (2001) Attention and symptom distress in women with and without breast cancer. Nurs Res 50:86–94. doi:10.1097/00006199-200103000-00004 PubMedCrossRefGoogle Scholar
  37. 37.
    Lehto RH, Cimprich B (1999) Anxiety and directed attention in women awaiting breast cancer surgery. Oncol Nurs Forum 26:767–772PubMedGoogle Scholar
  38. 38.
    Shilling V, Jenkins V, Fallowfield L et al (2003) The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 86:405–412. doi:10.1016/j.jsbmb.2003.07.001 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  1. 1.School of PsychologyUniversité Laval and Laval University Cancer Research CenterQuebecCanada

Personalised recommendations